Upstream Processing

Apr 01, 2017
BioPharm International
OrlaSURF technology can be used for the development of target-binding assays to monitor the binding of an ADC to its antigen.
Mar 01, 2017
BioPharm International
The decision to use disposable bioreactors is now driven by commercial rather than technological considerations.
Feb 27, 2017
By BioPharm International Editors
Sanofi and Lonza formed a joint venture to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Feb 22, 2017
By BioPharm International Editors
CellGenix will add R&D, production, and warehouse space in Freiburg, Germany for GMP-grade raw materials for cell therapy, gene-therapy, and tissue-engineered products.
Feb 21, 2017
By BioPharm International Editors
Under the agreement, Abzena will manufacture magacizumab, an antibody created using the ‘Abzena inside’ Composite Human Antibody technology.
Feb 07, 2017
By BioPharm International Editors
This three-year partnership will explore and identify new tools and methods to modify and optimize the Chinese hamster ovary (CHO) cell line performance.
Feb 01, 2017
BioPharm International
Pump systems must be designed to meet the needs of specific processes, including preventing cross-contamination and damage due to shear forces.
Feb 01, 2017
BioPharm International
A multi-pronged approach to raw materials testing can help mitigate the risk of future contamination events.
Jan 10, 2017
Language surrounding regenerative medicine and the REGROW Act appeared back into the 21st Century Cures Act right before it passed. What will this mean for the controversial testing and marketing of stem-cell therapies?
Jan 09, 2017
By BioPharm International Editors
UK-based Orchard Therapeutics and PharmaCell ally to support clinical trials and commercialization of Orchard’s ex-vivo gene therapies.
native1_300x100
lorem ipsum